Clobazam monotherapy for partial-onset or generalized-onset seizures

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Limited monotherapy options exist for new partial-onset or generalized-onset seizures.
• Clobazam monotherapy's role in treating new-onset or untreated seizures requires further definition.
• Gaps in evidence for clobazam monotherapy necessitate a systematic review.

Purpose of the Study:

• To evaluate clobazam's efficacy, effectiveness, tolerability, and safety as monotherapy.
• To assess clobazam in patients with new-onset partial or generalized seizures.

Main Methods:

• Systematic review of randomized or quasi-randomized controlled trials.
• Searched multiple databases including Cochrane, MEDLINE, DARE, and BIOSIS.
• Included trials comparing clobazam monotherapy to placebo or other anti-seizure medications.

Main Results:

• Two trials with 163 participants were identified; meta-analysis was not possible.
• Low-quality evidence showed no significant difference in 12-month retention between clobazam and carbamazepine.
• Low-quality evidence indicated a potential advantage of clobazam over phenytoin for retention.

Conclusions:

• Clobazam demonstrated no advantage over carbamazepine for 12-month retention in drug-naïve children.
• A slight advantage of clobazam over phenytoin for 6-month retention was observed in specific patient groups.
• Insufficient evidence currently exists to inform clinical practice regarding clobazam monotherapy.